Impact of new treatment options for hepatitis C virus infection in liver transplantation

Table 5 Anti-hepatitis C virus therapy in liver transplant recipients with recurrent hepatitis C virus infection: Outcome of main studies from the past 10 years

Ref.	Population	n	Treatment regimen	SVR	Adverse effects
Interferon (IFN) or pegylated interferon (Peg-IFN) plus ribavirin (RBV) regimens
Fernández et al[95], 2006	LTR with recurrent HCV	47	Peg-IFN/RBV	23%	21% SAE
Carrión et al[77], 2008	LTR with mild recurrence (F0-F2)	27	Peg-IFN/RBV	48%	56% discontinuation
Berenguer et al[92], 2008	LTR with recurrent HCV	89	IFN/RBV vs Peg-IFN/RBV	16% vs 48%	20% decompensation; 15% deaths
Hanouneh et al[93], 2008	LTR with recurrent HCV	53	Peg-IFN/RBV	35%	23% SAE
Ueda et al[146], 2010	LTR with recurrent HCV (G1)	34	Peg-IFN alfa-2b + RBV	50%	18% discontinuation
DAA triple therapy with Peg-IFN/RBV plus boceprevir (BOC) or telaprevir (TVR)
Verna et al[109], 2015	Advanced fibrosis (F > 3) and 9 FCH	49	Peg-IFN/RBV/TVR or BOC	51% AF 44% CH	22% AF and 33% CH decompensation
Pungpapong et al[108], 2013	LTR with recurrent HCV	60	Peg-IFN/RBV/TVR (35) or BOC (25)	67% TVR 45% BOC	12% decompensation, 2 deaths
Coilly et al[107], 2014	LTR with recurrent HCV	37	Peg-IFN/RBV/TVR (19) or BOC (18)	20% TVR 71% BOC	14% SAE, 27% infection, 3 deaths
IFN-free DAA regimens
Forns et al[111], 2015	Post-LT decompensated cirrhosis and FCH	92	SOF/RBV ± Peg-IFN 24-48 wk	59%	46% SAE
Charlton et al[110], 2015	LTR with recurrent HCV	40	SOF/RBV 24 wk	70%	No SAE
Reddy et al[44], 2015	Post LT recurrence (121 CPT B and C)	223	LDV/SOF/RBV 12 vs 24 wk	94% (60% CTP C)	4% SAE, 3% discontinuation
Gutierrez et al[118], 2015	Post LT recurrence	61	SOF/SMV ± RBV	93%	No SAE
Pungpapong et al[119], 2015	Post LT recurrence	123	SOF/SMV ± RBV	90%	1 death possibly related to treatment
Kwo et al[103], 2014	Post LT recurrence (G1)	34	Paritaprevir/r/Ombitasvir and Dasabuvir/RBV	97%	1 discontinuation
Poordad et al[85], 2015	Post LT recurrence	53	DCV/SOF/RBV 12 wk	94%	1 discontinuation (SVR); no SAE

LTR: Liver transplant recipients; SVR: Sustained virological response; CTP: Child-Turcotte-Pugh; SAE: Serious adverse event; FCH: Fibrosing cholestatic hepatitis; SOF: Sofosbuvir; SMV: Simeprevir; LDV: Ledipasvir; r: Ritonavir; DCV: Daclatasvir.